Genentech, the first publicly owned biotechnology company, recently completed an individualized neoantigen-specific immunotherapy (iNeST) facility on its campus in Hillsboro, Oregon. Using proprietary algorithms, the iNeST process involves DNA extraction from an individual patient's tumor cells and sequences, according to the company.